NTRA Key Statistics, Chart & Performance
The current stock price of NTRA is 203.04 USD. In the past month the price decreased by -15.24%. In the past year, price increased by 17.49%.
NTRA Technical Analysis
ChartMill assigns a technical rating of 1 / 10 to NTRA. When comparing the yearly performance of all stocks, NTRA turns out to be only a medium performer in the overall market: it outperformed 63.75% of all stocks.
NTRA Fundamental Analysis
ChartMill assigns a fundamental rating of 4 / 10 to NTRA. While NTRA has a great health rating, there are worries on its profitability.
NTRA Financial Highlights
Over the last trailing twelve months NTRA reported a non-GAAP Earnings per Share(EPS) of -2.29. The EPS decreased by -30.11% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -16.97% | ||
| ROE | -24.69% | ||
| Debt/Equity | 0.06 |
NTRA Forecast & Estimates
27 analysts have analysed NTRA and the average price target is 261 USD. This implies a price increase of 28.54% is expected in the next year compared to the current price of 203.04.
For the next year, analysts expect an EPS growth of -60.35% and a revenue growth 34.5% for NTRA
NTRA Ownership
NTRA Competitors/Peers
| Symbol | Company Name | Technical Rating | Fundamental Rating | FPE | Market Cap |
|---|---|---|---|---|---|
| ABBV | ABBVIE INC | 15.39 | 394.886B | ||
| AMGN | AMGEN INC | 17.06 | 206.949B | ||
| GILD | GILEAD SCIENCES INC | 17.1 | 189.204B | ||
| VRTX | VERTEX PHARMACEUTICALS INC | 23.44 | 121.258B | ||
| REGN | REGENERON PHARMACEUTICALS | 16.91 | 82.557B | ||
| ALNY | ALNYLAM PHARMACEUTICALS INC | 48.99 | 43.353B | ||
| INSM | INSMED INC | N/A | 31.961B | ||
| BIIB | BIOGEN INC | 13.22 | 29.513B | ||
| INCY | INCYTE CORP | 13.54 | 21.279B |
Related stock screener links
View all stocks in the Biotechnology Industry | View all stocks in the Health Care Sector | View all stocks on the Nasdaq Exchange | Find stocks with similar TA and Setup ratings on the USA exchanges | Find stocks with similar Fundamental rating on the USA exchanges | Find more growth stocks the USA exchanges | Find the competitors with the best technical ratings on the USA exchanges | Find the competitors with the best fundamentals on the USA exchanges | Find the competitors with the best valuation on the USA exchanges | Find the competitors with the best dividend on the USA exchanges | Find the competitors with the best analyst ratings on the USA exchanges
About NTRA
Company Profile
Natera, Inc. is a diagnostics company, which engages in the discovery, development, and commercialization of genetic testing services. The company is headquartered in Austin, Texas and currently employs 4,424 full-time employees. The company went IPO on 2015-07-02. The firm's cfDNA technology platform combines novel molecular biology techniques with bioinformatics software and artificial intelligence. The company has leveraged its platform to develop non-invasive prenatal test on the market (Panorama), the first tumor-specific assay for truly individualized cancer care (Signatera), best-in-class rejection assessment for kidney transplantation (Prospera) and others. In the women’s health space, it develops and commercializes non- or minimally- invasive tests to evaluate risk for, and thereby enable early detection of, a range of genetic conditions, such as Down syndrome. In oncology, it is focused on detecting molecular residual disease and recurrence monitoring in solid tumors, among others. In organ health, it offers tests to assess kidney, heart, and lung transplant rejection as well as genetic testing for chronic kidney disease.
Company Info
NATERA INC
13011 Mccallen Pass, Building A Suite 100
Austin TEXAS 78753 US
CEO: Steve Chapman
Employees: 4424
Phone: 16502499090
NATERA INC / NTRA FAQ
What does NATERA INC do?
Natera, Inc. is a diagnostics company, which engages in the discovery, development, and commercialization of genetic testing services. The company is headquartered in Austin, Texas and currently employs 4,424 full-time employees. The company went IPO on 2015-07-02. The firm's cfDNA technology platform combines novel molecular biology techniques with bioinformatics software and artificial intelligence. The company has leveraged its platform to develop non-invasive prenatal test on the market (Panorama), the first tumor-specific assay for truly individualized cancer care (Signatera), best-in-class rejection assessment for kidney transplantation (Prospera) and others. In the women’s health space, it develops and commercializes non- or minimally- invasive tests to evaluate risk for, and thereby enable early detection of, a range of genetic conditions, such as Down syndrome. In oncology, it is focused on detecting molecular residual disease and recurrence monitoring in solid tumors, among others. In organ health, it offers tests to assess kidney, heart, and lung transplant rejection as well as genetic testing for chronic kidney disease.
What is the stock price of NATERA INC today?
The current stock price of NTRA is 203.04 USD. The price increased by 3.02% in the last trading session.
Does NATERA INC pay dividends?
NTRA does not pay a dividend.
What is the ChartMill technical and fundamental rating of NTRA stock?
NTRA has a ChartMill Technical rating of 1 out of 10 and a ChartMill Fundamental rating of 4 out of 10.
How is the valuation of NATERA INC (NTRA) based on its PE ratio?
NATERA INC (NTRA) does not have a PE ratio as the earnings reported over the last twelve months were negative (-2.29).
Can you provide the number of employees for NATERA INC?
NATERA INC (NTRA) currently has 4424 employees.
What is the next earnings date for NTRA stock?
NATERA INC (NTRA) will report earnings on 2026-03-04, after the market close.